Vanguard Personalized Indexing Management LLC Makes New Investment in Lexeo Therapeutics, Inc. $LXEO

Vanguard Personalized Indexing Management LLC bought a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,000 shares of the company’s stock, valued at approximately $60,000.

Several other large investors have also recently modified their holdings of LXEO. Affinity Asset Advisors LLC bought a new position in Lexeo Therapeutics in the 1st quarter valued at $5,139,000. Millennium Management LLC raised its stake in Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock valued at $3,718,000 after buying an additional 929,538 shares during the last quarter. Privium Fund Management B.V. raised its stake in Lexeo Therapeutics by 16.0% in the first quarter. Privium Fund Management B.V. now owns 160,198 shares of the company’s stock valued at $556,000 after buying an additional 22,083 shares during the last quarter. Palumbo Wealth Management LLC purchased a new stake in Lexeo Therapeutics in the second quarter valued at about $226,000. Finally, AQR Capital Management LLC increased its holdings in shares of Lexeo Therapeutics by 370.0% in the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock valued at $175,000 after purchasing an additional 39,627 shares during the period. Institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on LXEO shares. Chardan Capital raised their target price on Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Leerink Partners lifted their price objective on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Guggenheim started coverage on Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright dropped their price objective on Lexeo Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, October 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lexeo Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $18.57.

Lexeo Therapeutics Trading Up 6.6%

NASDAQ LXEO opened at $9.84 on Tuesday. The stock has a market capitalization of $531.36 million, a price-to-earnings ratio of -3.02 and a beta of 1.66. The business’s 50 day moving average is $6.47 and its two-hundred day moving average is $4.72. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $11.72.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.04. Equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Tai Sandi See sold 3,888 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the sale, the insider directly owned 65,862 shares in the company, valued at approximately $588,806.28. This represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Adler sold 3,382 shares of the stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $30,235.08. Following the completion of the sale, the insider owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,091 shares of company stock valued at $232,007. 5.30% of the stock is currently owned by company insiders.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.